Medimmune Limited

Invox Pharma Limited

Michelle Morrow

Scott A Hammond

Ian Nevin Foltz

Jaspal Singh Kang

Matthieu Chodorge

Melanie Boyle

Laura Sekirov

Ross Anthony Stewart

Marat Alimzhanov

Christophe Queva

Kathleen Ann Mulgrew

Simon Dovedi

Changshou Gao

Claire Louise Dobson

Ronald Herbst

Darren Schofield

Godfrey Rainey

Stacey Drabic

Yariv Mazor

Srinath Kasturirangan

Michael Oberst

Brian Lobo

Prakash Manikwar

Jonathan Seaman

Gianluca Carlesso

Kristen Pollizzi

John Babcock

Edmund Poon

John Stephen Babcook

Mihriban Tuna

Miguel Gaspar

Robert Wilkinson

Tim Illidge

Ross A Steward

Scott Hammond

Ross Stewart

John Babcook

The present application relates to antibody molecules that bind and am able to agonise both CDand OX. The antibody molecules comprise a CDR-based binding site for CD, and an OXantigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer and infectious diseases.

Antibody molecules that bind CD137 and OX40

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Targeted binding agents against B7-H1

This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist, wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.

Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy

Growing community of inventors

Cambridge, United Kingdom

Michelle Morrow